OncoMatch/Clinical Trials/NCT05421663
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Is NCT05421663 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Prizloncabtagene autoleucel (Prizlo-Cel) for lymphoma, non-hodgkin.
Treatment: Prizloncabtagene autoleucel (Prizlo-Cel) — This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 overexpression
Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
Required: CD20 overexpression
Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks of apheresis
Autologous stem cell transplant within 12 weeks of apheresis
Cannot have received: CAR-T cell therapy
Exception: within 12 weeks of apheresis
Prior CAR-T cell therapy within 12 weeks of apheresis
Cannot have received: solid organ transplant
Any prior solid organ ... transplantation
Cannot have received: allogeneic stem cell transplant
Any prior ... allogeneic stem cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Colorado Blood Cancer Institute · Denver, Colorado
- University of Iowa Hospital and Clinics · Iowa City, Iowa
- University of Kentucky Medical Center · Lexington, Kentucky
- Rutgers Cancer Institute of New Jersey · Piscataway, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05421663 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, CAR-T cell therapy, solid organ transplant disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify